A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA ½ Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Phase II
Gary Goodman, M.D.
SWOG (Southwest Oncology Group)
Brenda Fisher

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.